Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

Univariate and multivariate analyses of potential prognostic factors for 1,015 women with recurrent breast cancer confirmed that the site of initial recurrence is an important determinant for predicting survival from the time of initial recurrence. However, both estrogen receptor (ER) status and axillary lymph node status at diagnosis, as well as the length of the disease-free interval, provide additional independent information for predicting patient survival after disease recurrence. Involved axillary lymph nodes at the time of initial diagnosis and/or lack of ERs may indicate a highly malignant tumor or a weak host defense, either of which might be related to short survival after relapse. Patients with ER-negative tumors recurred more often in visceral and soft-tissue sites, while patients with ER-positive tumors were more likely to recur in bony sites. However, for each metastatic site, receptor-positive patients had longer survival

[1]  G. Hortobagyi,et al.  Multivariate analysis of prognostic factors in metastatic breast cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Blamey,et al.  Oestrogen-receptor status and sites of metastasis in breast cancer. , 1981, British Journal of Cancer.

[3]  J. Devitt The clinical stages of breast cancer--what do they mean? , 1967, Canadian Medical Association journal.

[4]  W. McGuire,et al.  Multiple estrogen receptor assays in human breast cancer. , 1983, Cancer research.

[5]  G. Hortobagyi,et al.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy. , 1979, Cancer research.

[6]  J. Meyer,et al.  Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. , 1980, Cancer research.

[7]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[8]  J. Lefante,et al.  Southeastern Cancer Study Group: breast cancer studies 1972-1982. , 1983, International journal of radiation oncology, biology, physics.

[9]  G. Bonadonna,et al.  Advanced breast cancer: are the traditional stratification parameters still of value when patients are treated with combination chemotherapy? , 1979, European journal of cancer.

[10]  Y. Lee,et al.  Steroid receptors study in breast carcinoma. , 1978, Medical and pediatric oncology.

[11]  Escher Gc,et al.  ADVANCED BREAST CARCINOMA-FACTORS INFLUENCING SURVIVAL. , 1963 .

[12]  R. Rubens,et al.  Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. , 1981, European journal of cancer.

[13]  W. McGuire,et al.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. McGuire,et al.  Multiple progesterone receptor assays in human breast cancer. , 1984, Cancer research.

[15]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[16]  S. Cutler,et al.  Classification of patients with disseminated cancer of the breast , 1969, Cancer.

[17]  W. Drobyski,et al.  Estrogen receptors and the pattern of relapse in breast cancer. , 1984, Archives of internal medicine.

[18]  M. DeLaGarza,et al.  Evaluation of estrogen receptor assays in human breast cancer tissue. , 1977 .

[19]  J. Devitt The enigmatic behavior of breast cancer , 1971, Cancer.

[20]  J. Pater,et al.  Survival after recurrence of breast cancer. , 1981, Canadian Medical Association journal.

[21]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[22]  D. Cox Regression Models and Life-Tables , 1972 .

[23]  H. Potter,et al.  Estrogen Receptor and Natural Course of Breast Cancer , 1976, Annals of surgery.